NCT00046748.
Methods | Randomised, double‐blind, parallel‐group study |
Participants | Adults and adolescents with severe persistent asthma |
Interventions | Subcutaneous omalizumab versus placebo |
Outcomes | Clinically significant asthma exacerbation Medical resource utilisation Time to first asthma exacerbation Quality of life assessment at baseline, last visit Frequency of asthma rescue medication use Safety/tolerability of omalizumab |
Notes | No data available at time of completion of 2012 update of this review |